This brief uses data from the MN APCD to estimate how many Minnesotans may be eligible for FDA-approved gene therapies for nine rare diseases. (June 2026)

MDH released the Minnesota Prescription Drug Transparency 2026 Report to the Minnesota Legislature. It presents analysis of information reported to MDH through the first half of 2025 and assesses the Act's progress toward statutory goals.

This snapshot provides prevalence and demographic information on patients with sickle cell disease and sickle cell trait in Minnesota using 2023 data from the MN APCD and other data sources. (March 2026)

The Minnesota Department of Health (MDH) annually produces and sends the 340B Covered Entity Report to the Minnesota Legislature. The report provides a summary and analysis of the information submitted to MDH related to Minnesota covered entities' participation in the federal 340B Drug Pricing Program in the prior calendar year.

This section provides information on key enrollment and spending trends in publicly-financed health insurance programs that cover Minnesotans, including Medicare, Medical Assistance (Medicaid) and MinnesotaCare. (Last update: February 2026)

This section provides an overview of the market for employer-based health insurance in Minnesota, using pooled data from the Insurance Component of the federal Medical Expenditure Panel Survey. It includes information on variations in health insurance offer rates, employee eligibility, take-up rates, total premiums and employer/employee shares, and other enrollee cost sharing requirements. The supplement contains details on the cost of coverage and cost sharing for employee plus one and family coverage. (Last update: January 2026)

This brief relies upon data from the MN APCD and methods developed by the Health Care Cost Institute (HCCI) to produce population-based estimates of spending, prices, and utilization for medical care and prescription drugs. (September 2025)